{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:52:04Z","timestamp":1789685524432,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-026-06131-2","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:29:10Z","timestamp":1779200950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High 12-month persistence and effectiveness of IL-23 inhibitors in psoriatic arthritis: a multicenter retrospective real-world study from Argentina"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5928-1092","authenticated-orcid":false,"given":"Rodrigo","family":"Garcia-Salinas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-7559","authenticated-orcid":false,"given":"Fernando","family":"Sommerfleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3222-8574","authenticated-orcid":false,"given":"Alejandro","family":"Benitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9799-1118","authenticated-orcid":false,"given":"Analia","family":"Dellepiane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0519-8012","authenticated-orcid":false,"given":"Adrian","family":"Estevez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6836-2352","authenticated-orcid":false,"given":"Maximiliano","family":"Fenucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gimena","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"6131_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376:957\u2013970. https:\/\/doi.org\/10.1056\/NEJMra1505557","journal-title":"N Engl J Med"},{"key":"6131_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N et al (2022) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 18:465\u2013479. https:\/\/doi.org\/10.1038\/s41584-022-00798-0","journal-title":"Nat Rev Rheumatol"},{"key":"6131_CR3","doi-asserted-by":"publisher","unstructured":"Krueger JG, Eyerich K, Kuchroo VK, et al (2024) IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1331217","DOI":"10.3389\/fimmu.2024.1331217"},{"key":"6131_CR4","doi-asserted-by":"publisher","unstructured":"Merola JF, Armstrong A, Khattri S, et al (2024) Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatol Treat. https:\/\/doi.org\/10.1080\/09546634.2024.2342383","DOI":"10.1080\/09546634.2024.2342383"},{"key":"6131_CR5","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke W-H et al (2020) Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395:1115\u20131125. https:\/\/doi.org\/10.1016\/S0140-6736(20)30265-8","journal-title":"Lancet"},{"key":"6131_CR6","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1007\/s00296-024-05722-1","volume":"44","author":"D Boboryko","year":"2024","unstructured":"Boboryko D, Olejnik-Wojciechowska J, Baranowska M et al (2024) Biological therapy for psoriatic arthritis: current state and future perspectives. Rheumatol Int 44:2711\u20132725. https:\/\/doi.org\/10.1007\/s00296-024-05722-1","journal-title":"Rheumatol Int"},{"key":"6131_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2133531","author":"CDB Elgaard","year":"2023","unstructured":"Elgaard CDB, Iversen L, Hjuler KF (2023) Guselkumab, Tildrakizumab, and Risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatolog Treat. https:\/\/doi.org\/10.1080\/09546634.2022.2133531","journal-title":"J Dermatolog Treat"},{"key":"6131_CR8","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/1756-185X.14663","volume":"26","author":"T Ak","year":"2023","unstructured":"Ak T, Temiz SNY, Taner M et al (2023) Effectiveness of anti-interleukin-23 therapy in psoriatic arthritis: a pilot prospective real-world study. Int J Rheum Dis 26:878\u2013884. https:\/\/doi.org\/10.1111\/1756-185X.14663","journal-title":"Int J Rheum Dis"},{"key":"6131_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/rheumatology\/keab509","volume":"61","author":"I Pantano","year":"2022","unstructured":"Pantano I, Mauro D, Romano F et al (2022) Real-life efficacy of Guselkumab in patients with early psoriatic arthritis. Rheumatol (UK) 61:1217\u20131221. https:\/\/doi.org\/10.1093\/rheumatology\/keab509","journal-title":"Rheumatol (UK)"},{"key":"6131_CR10","doi-asserted-by":"publisher","unstructured":"Rocamora V, Crespi L, Ferran M, et al (2022) Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: multicenter analysis in daily clinical practice by the Spanish Psoriasis Group. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.15865","DOI":"10.1111\/dth.15865"},{"key":"6131_CR11","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1111\/ijd.16849","volume":"62","author":"AG Vaiopoulos","year":"2023","unstructured":"Vaiopoulos AG, Dalamaga M, Katsimbri P et al (2023) Real-world data show high efficacy of IL23 inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult-to-treat areas. Int J Dermatol 62:1404\u20131413. https:\/\/doi.org\/10.1111\/ijd.16849","journal-title":"Int J Dermatol"},{"key":"6131_CR12","doi-asserted-by":"publisher","unstructured":"Foti R, Amato G, Visalli E, et al (2025) Guselkumab in psoriatic arthritis: therapeutic impact on axial and peripheral involvement\u2014monocentric real-world evidence. J Clin Med. https:\/\/doi.org\/10.3390\/jcm14093151","DOI":"10.3390\/jcm14093151"},{"key":"6131_CR13","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1093\/rheumatology\/keae220","volume":"64","author":"P Ruscitti","year":"2025","unstructured":"Ruscitti P, Pantano I, Cataldi G et al (2025) Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort. Rheumatology 64:1122\u20131130. https:\/\/doi.org\/10.1093\/rheumatology\/keae220","journal-title":"Rheumatology"},{"key":"6131_CR14","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","volume":"158","author":"ZZN Yiu","year":"2022","unstructured":"Yiu ZZN, Becher G, Kirby B et al (2022) Drug survival associated with effectiveness and safety of treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in patients with psoriasis. JAMA Dermatol 158:1131\u20131141. https:\/\/doi.org\/10.1001\/jamadermatol.2022.2909","journal-title":"JAMA Dermatol"},{"key":"6131_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s40801-022-00326-2","volume":"9","author":"PJ Mease","year":"2022","unstructured":"Mease PJ, Ogdie A, Chakravarty SD et al (2022) Clinical characteristics of registry participants with psoriatic arthritis initiating Guselkumab: an analysis from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry. Drugs Real World Outcomes 9:617\u2013628. https:\/\/doi.org\/10.1007\/s40801-022-00326-2","journal-title":"Drugs Real World Outcomes"},{"key":"6131_CR16","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40744-023-00582-w","volume":"10","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Ogdie A, Tesser J et al (2023) Six-month persistence and multi-domain effectiveness of Guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas Psoriatic Arthritis\/Spondyloarthritis Registry. Rheumatol Ther 10:1479\u20131501. https:\/\/doi.org\/10.1007\/s40744-023-00582-w","journal-title":"Rheumatol Ther"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06131-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06131-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06131-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:39:07Z","timestamp":1783525147000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06131-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["6131"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06131-2","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare they have no others conflict of interest regarding the present study. The authors declare that this manuscript is original, has not been published previously, and is not under consideration for publication elsewhere, in whole or in part.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Artificial Intelligence tools (ChatGPT, GPT-5, OpenAI) were used to assist with English editing during manuscript preparation. All outputs generated by AI were carefully reviewed and edited by the authors to ensure accuracy and appropriateness.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of artificial intelligence"}}],"article-number":"94"}}